TRDA- Entrada Therapeutics, Inc.

Name: Entrada Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Entrada Therapeutics, Inc. (TRDA) has 7 insiders with recent SEC Form 4 filings, including 0 buys and 27 sells. TRDA is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	5am Ventures V, L.P.	2.96M	$21.01M	-
10%	Parmar Kush	2.96M	$21.01M	-
CEO	Doshi Dipal	526.0K	$3.73M	-
10%	Baker Bros. Advisors LP	381.3K	$2.70M	-
Pres	Sethuraman Natarajan	216.3K	$1.53M	-

Activity

Buys and sells only

Transactions

10 filings · page 2

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jul 9, 2025	Parmar Kush67	Director, 10% Owner	Sell	27,000	$7.50	$202,554.00	-0.6%	-22.7%	-
Jul 1, 2025	Parmar Kush67	-	Sell	125,000	$6.93	$866,632.50	-1.0%	-17.9%	-
Jul 1, 2025	5am Ventures V, L.P.72	-	Sell	125,000	$6.93	$866,632.50	-1.0%	-17.9%	-
Mar 17, 2025	Wentworth Kory James61	Chief Financial Officer	Sell	1,784	$10.67	$19,035.28	-1.6%	-31.5%	+16.5%
Dec 11, 2024	Mpm Bioventures 2014, L.P.67	10% Owner	Sell	44,722	$20.51	$917,110.96	-0.5%	-46.5%	-45.7%
Dec 11, 2024	Mpm Bioventures 2018, L.P.54	10% Owner	Sell	44,722	$20.51	$917,110.96	-0.5%	-46.5%	-45.7%
Dec 3, 2024	Sethuraman Natarajan83	President, Research &Develop.	Sell	15,891	$20.18	$320,619.70	-3.3%	-43.8%	-50.1%
Dec 2, 2024	Wentworth Kory James61	Chief Financial Officer	Sale+OE	6,000	$19.99	$119,948.30	-3.9%	-44.2%	-51.5%
Nov 13, 2024	Sethuraman Natarajan83	President, Research &Develop.	Sell	4,109	$20.03	$82,299.94	-1.3%	-38.7%	-56.0%
Nov 11, 2024	Wentworth Kory James61	Chief Financial Officer	Sale+OE	8,637	$19.98	$172,562.08	-10.5%	-35.3%	-61.3%

← PrevPage 2Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC